Skip to content

Market/Novel Tech

GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced results from a new meta-analyses proposing that those treated with LUMEVOQ… Read More »GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.

Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a first-patient-dosed for a Phase 1/2 clinical trial.  This… Read More »Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.